Open AccessNivolumab + Cabozantinib Sustains Survival Benefits in Kidney Cancer
Author(s) -
Mark L. Fuerst
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000741776.30420.69
Subject(s) - cabozantinib , nivolumab , medicine , sunitinib , ipilimumab , kidney cancer , renal cell carcinoma , oncology , cancer , progression free survival , immunotherapy , overall survival